Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at email@example.com or find her on LinkedIn.
Articles by Tracy Staton
Novartis won't have to wait for European regulators to do a full-force data sift before its new heart failure drug becomes available in England. The U.K. will allow Novartis to roll out its Entresto drug under an early-access scheme begun last year.
It's no secret that pharma salespeople are barred at the doors of many doctors' offices. Those doors have been closing one by one for several years. But now, more than half of physician practices restrict reps' access--and in some specialties, only one in five doctors are rep-friendly.
When Amgen rolled out its Blincyto treatment for an ultra-rare form of leukemia, the California biotech set what seemed to be an eye-watering price--$178,000 for a typical patient. But some number-crunching of clinical trial data, coupled with documents from the Centers for Medicare and Medicaid Services, suggests that the real-world cost will be much lower.
Last week, Amgen won its much-anticipated FDA approval for the PCSK9 cholesterol-fighter Repatha and promptly set a price of $14,100 per year. But even after pharmacy benefits managers and insurers wring out their discounts, the cost is unlikely to be nearly as low as Repatha's price tag in Europe.
A new drug for blood cancer from Bristol-Myers Squibb and AbbVie is on the fast track to FDA approval, winning a priority review to treat multiple myeloma.
Sen. Bernie Sanders, a longtime pharma watchdog, says he's rolling out legislation to stall drug price hikes. The presidential candidate's proposals include some previously failed measures--including Medicare price negotiations--but they come at a time when public debate about the rising cost of meds has reached a fever pitch.
Hedge funder Kyle Bass says his pharma patent challenges may be a moneymaking strategy--but that doesn't mean they're not beneficial to society, too. And according to a new analysis by the Congressional Budget Office (CBO), he's right.
As if last week's Jardiance news wasn't enough to worry makers of DPP-4 diabetes drugs, the FDA has now issued a warning that the class of meds might cause "severe and disabling" joint pain.
After announcing a $2 billion manufacturing investment Wednesday--and launching a late-stage trial of its oral semaglutide drug to boot--the Danish drugmaker now says it's buying two private biopharma research companies specializing in diabetes and related metabolic problems.
After much industry lobbying and public debate, the FDA has proposed a system for naming biosimilar drugs. It's a sort of hybrid of the generic name on one hand and the unique brand name on the other. And it would allow the FDA to make some biosims easy to substitute for the brand-name original--and others not so easy.